ReviewClinical microbiology reviews2001
Antifungal susceptibility testing: practical aspects and current challenges.
Review in Clinical microbiology reviews, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
124 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts.Intensive care medicine · 2013Guideline
- Association between in vitro susceptibility to natamycin and voriconazole and clinical outcomes in fungal keratitis.Ophthalmology · 2014Trial
- Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.Antimicrobial agents and chemotherapy · 2005Trial
- Prevalence, antifungal susceptibility, and virulence determinants of Candida species causing vulvovaginal candidiasis in pregnant women in Saudi Arabia.Antonie van Leeuwenhoek · 2026Article
- Genomic Insights intoJournal of fungi (Basel, Switzerland) · 2026Article
- The impact of respiratory tract mimicking media on antifungal susceptibility testing.Antimicrobial agents and chemotherapy · 2025Article
- Voriconazole Pharmacokinetics Administered at 4 mg/kg IM and IV in Nursehound Sharks (Veterinary sciences · 2025Article
- Article
- The Influence of Medium Composition on EUCAST and Etest Antifungal Susceptibility Testing.Journal of fungi (Basel, Switzerland) · 2023Article
- Antifungal Susceptibility of OralJournal of fungi (Basel, Switzerland) · 2023Article
- Cryptococcus neoformans, a global threat to human health.Infectious diseases of poverty · 2023Review
- Aggregation-induced emission biomaterials for anti-pathogen medical applications: detecting, imaging and killing.Regenerative biomaterials · 2023Review
- Synthesis, Biological Evaluation, and Structure-Activity Relationships of 4-Aminopiperidines as Novel Antifungal Agents Targeting Ergosterol Biosynthesis.Molecules (Basel, Switzerland) · 2021Article
- Antifungal Susceptibility Testing: A Primer for Clinicians.Open forum infectious diseases · 2021Review
- A Paradigm Shift in the Treatment and Management of Onychomycosis.Skin appendage disorders · 2021Review
- Antifungal Activity of the Sesquiterpene Lactones fromPlants (Basel, Switzerland) · 2021Article
- Isolation of diverse bioactive compounds fromSaudi journal of biological sciences · 2021Article
- Article
- PREVALENCE, IDENTIFICATION AND ANTIFUNGAL SUSCEPTIBILITY OF DERMATOPHYTES CAUSING TINEA CAPITIS IN A LOCALITY OF NORTH CENTRAL NIGERIA.African journal of infectious diseases · 2021Article
- Antifungal Resistance RegardingJournal of fungi (Basel, Switzerland) · 2020Review
64 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Development of standardized antifungal susceptibility testing methods has been the focus of intensive research for the last 15 years. Reference methods for yeasts (NCCLS M27-A) and molds (M38-P) are now available. The development of these methods provides researchers not only with standardized methods for testing but also with an understanding of the variables that affect interlaboratory reproducibility. With this knowledge, we have now moved into the phase of (i) demonstrating the clinical value (or lack thereof) of standardized methods, (ii) developing modifications to these reference methods that address specific problems, and (iii) developing reliable commercial test kits. Clinically relevant testing is now available for selected fungi and drugs: Candida spp. against fluconazole, itraconazole, flucytosine, and (perhaps) amphotericin B; Cryptococcus neoformans against (perhaps) fluconazole and amphotericin B; and Aspergillus spp. against (perhaps) itraconazole. Expanding the range of useful testing procedures is the current focus of research in this area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.